However, we should keep in mind that the MIST-2 trial was done in 2011 and that studies that include patients before that may not have used tPA/DNAse as standard nonsurgical management of empyema, with reports of only 3%-20% of patients receiving fibrinolytics [8,9,15]. This evidence concerns the gene PLAT and empyema.